Anti-CTLA-4 Antibody [PS01-34]
HA721269
ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin, Other Application
Product group Antibodies
TargetCTLA4
Overview
- SupplierHUABIO
- Product NameAnti-CTLA-4 Antibody [PS01-34]
- Delivery Days Customer2
- ApplicationsImmunoHistoChemistry, ImmunoHistoChemistry Paraffin, Other Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDPS01-34
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID1493
- Target nameCTLA4
- Target descriptioncytotoxic T-lymphocyte associated protein 4
- Target synonymsALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12, cytotoxic T-lymphocyte protein 4, celiac disease 3, cytotoxic T lymphocyte associated antigen 4 short spliced form, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
- HostRabbit
- IsotypeIgG
- Protein IDP09793
- Protein NameCytotoxic T-lymphocyte protein 4
- Scientific DescriptionCTLA-4 or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation - a phenomenon which is particularly notable in cancers. It acts as an off switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. Variants in this gene have been associated with Type 1 diabetes, Graves disease, Hashimotos thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, primary biliary cirrhosis and other autoimmune diseases. Polymorphisms of the CTLA-4 gene are associated with autoimmune diseases such as rheumatoid arthritis, autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In systemic lupus erythematosus (SLE), the splice variant sCTLA-4 is found to be aberrantly produced and found in the serum of patients with active SLE. Germline haploinsufficiency of CTLA-4 leads to CTLA-4 deficiency or CHAI disease (CTLA4 haploinsufficiency with autoimmune infiltration), a rare genetic disorder of the immune system. Symptomatic patients with CTLA-4 mutations are characterized by an immune dysregulation syndrome including extensive T cell infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system. Once a diagnosis is made, the treatment is based on an individuals clinical condition and may include standard management for autoimmunity and immunoglobulin deficiencies. The comparatively higher binding affinity of CTLA-4 than CD28 has made it a potential therapy for autoimmune diseases.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC41116161